US › Healthcare

Metagenomi, Inc. Common Stock (MGX)

US · Healthcare · Biotechnology

$0.78-7.24%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$-257,000

Revenue YoY

-103.0%

Net profit

$-27.5M

EPS

$-0.73

EPS estimate

$-0.63

EPS came in at -0.73 against a street estimate of -0.63 — a miss of 15.9%.

Key statistics

Market cap

$31.9M

Forward P/E

0.0

P/B

0.38

Book value

$2.98

EPS (TTM)

$-2.31

52-week high

$3.40

52-week low

$0.77

50-day MA

$1.14

200-day MA

$1.35

Beta

0.70

Analyst view

with an average price target of $7.00.

Shareholding

Insiders

19.02%

Institutions

18.72%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.85%
Renaissance Technologies Corp	1.97%
Catalio Capital Management, LP	1.40%
Peapod Lane Capital LLC	1.39%
Two Sigma Investments LLC	1.36%
Bridgeway Capital Management, LLC	1.06%
Wells Fargo & Co	1.00%
Geode Capital Management, LLC	0.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Metagenomi, Inc. Common Stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.